Siegfried Reported Higher Sales in First Half 2026
The pharmaceutical company achieved CHF 633 million in sales while integrating new global manufacturing assets.
Updated on Sept. 24, 2026 in Corporate Finance
Live Poll
Do you trust large pharmaceutical companies to successfully manage international growth through corporate acquisitions?
Siegfried announced that net sales reached CHF 633 million for the first half of 2026. The performance was supported by strong demand for its development and manufacturing services.
Why it matters
The results reflect the success of the company's EVOLVE+ strategy, which prioritizes operational excellence and strategic acquisitions. These efforts aim to stabilize long-term growth across diverse international markets.
Net sales hit CHF 633 million with a core EBITDA of CHF 142 million and a margin of 22.4%. Core net profit for the six-month period reached CHF 68.2 million.
The players
Siegfried
This is a global pharmaceutical company providing contract development and manufacturing services.
DINAMIQS
This subsidiary received a production license from Swissmedic for its viral vector manufacturing operations.
The details
Siegfried completed the acquisition of three drug substance manufacturing sites in the US and Australia on May 1, 2026. Additionally, the company inaugurated a large-scale manufacturing facility in Minden, Germany, in June 2026 to enhance capacity.
Timeline
May 1, 2026: The company finalized the acquisition of three drug substance facilities.
June 2026: Siegfried opened a large-scale manufacturing plant in Minden, Germany.
First half 2026: The financial results cover this six-month reporting period.
Market Dynamics
Siegfried follows the broader CDMO industry trend of using targeted M&A and capacity expansion to scale operations globally. By integrating these new sites, the company positions itself to capture more demand for complex drug substance manufacturing.
Shareholders and stakeholders should note that the firm expects USD 100 million in additional sales from newly acquired assets in 2026. The projected core EBITDA margin of over 23% serves as a key metric for evaluating the company's operational efficiency.
The takeaway
Siegfried continues to scale its global manufacturing presence to meet sustained service demand. Investors should monitor how the integration of new sites contributes to the company's full-year growth targets.
Further reading
Explore more analysis regarding industry trends in Corporate Finance.
Source note: This article includes information reported by Pharmaceuticalonline.
Live Poll
Do you trust large pharmaceutical companies to successfully manage international growth through corporate acquisitions?
